Scopio Labs Raises $50M For Its Cell Imaging Platform

Israeli digital microscopy company, Scopio Labs, secured a $50 million investment in Series C funding led by venture firms, OurCrowd, Aurum Ventures, Mizrahi-Tefahot Bank Invest, and Ilex Medical, the company announced on Tuesday. 

The company said it will use the new investment to double its employee roster and continue to expand its strategic partnerships and sales and enhance its software’s technological functions. 

Founded in 2015 by Itai Hayut and Erez Na’aman, Scopio Labs’ imaging platform uses computational photography and an AI-driven Decision Support System (DSS) to digitize, quantify, and analyze hematology and cytology cell samples with ultra-high resolution. This service makes identifying potential cell abnormalities easier and more precise, enabling hematopathologists to zoom in on the finest of details. 

In addition, Scopio Labs has built and integrated various AI and remote consultation solutions for large and small-scale labs and hospitals as a means of upgrading diagnostic processes and minimizing turnaround time. Other AI solutions including “bone marrow aspirates (BMA)” are currently in development.

“Deep learning can analyze hundreds of times more healthcare data from a patient, supporting physician decisions and detecting conditions like cancers, anemias, and bleeding disorders, as well as infections and allergies,” said Scopio co-founder and CEO Itai Hayut. “But for us, it all begins with high-quality digital imaging data.” 

“In the 21st century, people shouldn’t be looking through microscopes, manually counting cells,” Hayut continued. “Scopio’s full-field imaging and AI platform means tens of thousands of cells in a single sample can be examined, counted and analyzed instantly and reviewed by a specialist regardless of location, leading to faster, easier and earlier detection and diagnosis of cancers and many other life-threatening medical conditions.”

Scopio Labs’ imaging platform is now in use in major laboratories and medical centers worldwide, and its  FDA-cleared Full-Field Peripheral Blood Smear (FF PBS) application, as well as its ScopioVet veterinary application, are in full commercial use throughout the US and Europe